Century Therapeutics (NASDAQ:IPSC) Receives “Buy” Rating from HC Wainwright

Century Therapeutics (NASDAQ:IPSC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 457.29% from the stock’s current price.

Several other research analysts have also issued reports on the company. Piper Sandler lowered their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research report on Monday, December 30th. Chardan Capital cut their price objective on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Century Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Trading Down 1.3 %

Century Therapeutics stock opened at $0.90 on Wednesday. The stock has a 50-day moving average price of $1.19 and a two-hundred day moving average price of $1.57. Century Therapeutics has a 12 month low of $0.87 and a 12 month high of $5.51. The company has a market capitalization of $76.29 million, a PE ratio of -0.48 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The business had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. During the same period last year, the company earned ($0.55) EPS. As a group, analysts predict that Century Therapeutics will post -1.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IPSC. Bank of New York Mellon Corp grew its stake in Century Therapeutics by 110.1% during the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after purchasing an additional 78,088 shares during the period. Rhumbline Advisers grew its position in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after buying an additional 18,828 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Century Therapeutics by 141.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after acquiring an additional 44,155 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock valued at $422,000 after acquiring an additional 9,500 shares during the period. Finally, SG Americas Securities LLC bought a new position in Century Therapeutics during the third quarter worth $27,000. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.